KPV
Lys-Pro-Val · KPV Tripeptide · Alpha-MSH Fragment
A tiny three-amino-acid fragment of alpha-MSH that packs serious anti-inflammatory punch — especially for the gut.
What is KPV?
KPV is a tripeptide (just three amino acids: lysine-proline-valine) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It is one of the smallest bioactive peptides being used in biohacking, and its size is actually an advantage — small peptides tend to be more stable and potentially orally bioavailable.
The excitement around KPV centres on inflammatory bowel conditions. Research shows it can reduce intestinal inflammation through NF-kB inhibition, and some clinicians are using it for IBD, IBS, and general gut inflammation. It appears to work both systemically (injectable/oral) and locally when delivered directly to the gut.
What makes KPV interesting compared to other anti-inflammatory peptides is its safety profile. Being a naturally-occurring fragment of a hormone your body already makes, it seems to be exceptionally well-tolerated. The biohacking community has embraced it as a gentler alternative to pharmaceutical immunosuppressants for chronic gut issues.
How Does It Work?
KPV enters cells and directly inhibits the NF-kB inflammatory pathway — specifically by preventing IKK-beta activation and subsequent nuclear translocation of NF-kB. This reduces production of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta).
It also appears to interact with melanocortin receptors (MC1R) peripherally, though its intracellular NF-kB inhibition may be the primary mechanism. In the gut, it reduces epithelial cell inflammatory signalling and may support barrier integrity. Some evidence suggests antimicrobial properties as well.
What Does The Research Say?
Moderate evidence. Some human data, mostly animal studies.
Preclinical research is promising: multiple animal studies show KPV reduces colitis severity, decreases inflammatory markers, and improves gut histology. In vitro studies confirm NF-kB inhibition in intestinal epithelial cells.
Human clinical data is very limited — mostly case reports and clinical observations from functional medicine practitioners. No completed randomised controlled trials in humans as of yet. The preclinical signal is strong enough that human trials should be coming, but we are not there yet.
Reported Dosages
These are dosages reported in research literature and community reports. They are NOT medical recommendations. Always consult a healthcare professional.
Oral/sublingual: 200-500mcg once or twice daily (for gut-targeted effects, some practitioners use oral BPC-157 + KPV combined).
Subcutaneous: 200-500mcg daily.
Some compounding pharmacies offer suppository forms for direct colonic delivery.
DISCLAIMER: This is a research peptide without FDA/MHRA approval for human use. Clinical data is preclinical only. Work with a knowledgeable practitioner.
Side Effects & Risks
Reported side effects are minimal in anecdotal use — mild injection site reactions with subcutaneous administration. Being a fragment of an endogenous hormone, systemic toxicity appears low. However, long-term human safety data does not exist. Theoretical concern: immunosuppression with chronic use at high doses.
Legal Status by Country
Unregulated research peptide. Grey market availability.
Research chemical. Not FDA-approved. Available from peptide suppliers.
Unregulated in most EU countries. Not approved as medication.
Not TGA-approved. Research chemical status.
Important Disclaimer
This profile is for educational and research purposes only. It does not constitute medical advice. KPV may be regulated or illegal in your jurisdiction. Do not use any compound without consulting a qualified healthcare professional. StackPedia does not sell, supply, or promote the use of any controlled substance.